GLP-1 Savings Cards & Cash Prices: How to Pay Less in 2026

The list price (the sticker price before any discounts) for brand-name GLP-1 medications like Wegovy (semaglutide) and Zepbound (tirzepatide) still runs above $1,000 per month in 2026. Almost nobody pays that full amount, though. What you actually pay depends on three things: whether you have insurance, whether that insurance covers weight-loss medication, and which discount programs you qualify for.

There are really two worlds here. If your commercial (employer or marketplace) insurance covers the drug, a manufacturer savings card can bring your monthly copay down to as little as $25. If your insurance does not cover it — or you have no insurance — you fall into the cash-pay world, where the manufacturers now sell directly to patients at a steep discount from list price. Understanding which world you're in is the single most important step to lowering your bill.

Throughout this guide, prices reflect publicly posted 2026 manufacturer programs. These change often, so always confirm the current figure on the official NovoCare (Wegovy) or LillyDirect (Zepbound) pages before you commit.

A savings card (also called a copay card) is a discount program run by the drug's manufacturer that reduces your out-of-pocket copay at the pharmacy. For Wegovy, Novo Nordisk offers a card; for Zepbound, Eli Lilly offers one. In 2026 both can bring covered patients down to roughly $25 per month.

The catch is eligibility. Savings cards are designed for people with commercial insurance — a plan through an employer or the ACA marketplace. If your commercial plan already covers the medication, the card fills in most of the copay gap. If your commercial plan does not cover weight-loss drugs, some cards still offer a smaller discount off the cash price, but the savings are more modest.

The biggest limitation: savings cards cannot legally be used with government insurance — that means Medicare, Medicaid, TRICARE, and VA coverage are all excluded. This is a federal anti-kickback rule, not a company choice. If you're on Medicare, you'll need a different path, which we cover in our guide to [whether Medicare covers GLP-1 medications](/blog/does-medicare-cover-glp1-weight-loss-2026-bridge-program).

To enroll, you typically sign up on the manufacturer's website, get a card or code, and present it at the pharmacy along with your insurance. It takes minutes and is free.

If insurance won't cover your GLP-1, the direct-to-consumer cash programs are usually your cheapest legitimate option in 2026. Both manufacturers now sell straight to patients, skipping much of the traditional pharmacy markup.

For Wegovy, Novo Nordisk's NovoCare pharmacy sells self-pay pens starting around $199 per month for the first two fills for new patients (an introductory rate posted through the end of 2026), then roughly $349/month for maintenance. A flat self-pay option around $499/month is also available regardless of dose.

For Zepbound, Eli Lilly's LillyDirect sells single-dose vials starting around $299/month for the lowest dose, with higher doses priced higher (roughly $349–$499 depending on strength). The KwikPen self-pay option is priced similarly by dose.

These numbers move, and each program has its own rules about who counts as a "new" patient and how long introductory pricing lasts. Still, the takeaway is stable: paying cash through the manufacturer is dramatically cheaper than the $1,000+ list price. If you're weighing which drug to start, our comparison of [tirzepatide versus semaglutide](/blog/tirzepatide-vs-semaglutide-which-works-better-2026) can help you factor effectiveness alongside cost.

Compounded GLP-1s are versions of semaglutide or tirzepatide mixed by a compounding pharmacy rather than made by the brand manufacturer. During the 2023–2024 shortages, they were widely available and often cost $150–$300/month, which drew a lot of budget-conscious patients.

The picture is more complicated in 2026. Once the FDA declared the shortages resolved, large-scale compounding of these drugs became legally restricted, and the FDA has warned about dosing errors and inconsistent quality in some compounded products. Compounded versions are not FDA-approved, meaning they don't go through the same testing for purity, potency, and safety as brand drugs.

That doesn't make every compounded product dangerous, but it does mean you're taking on more uncertainty to save money. If you're considering this route, use a reputable pharmacy tied to a licensed telehealth provider, ask exactly what's in the vial and at what concentration, and read our deeper breakdown of [compounded versus brand GLP-1s](/blog/compounded-vs-brand-glp1-whats-the-difference) before deciding. For many people, a manufacturer cash program now offers comparable pricing with far more quality assurance.

Yes. A Flexible Spending Account (FSA) or Health Savings Account (HSA) can be used to pay for GLP-1 medications when they're prescribed by a licensed provider for a medical condition such as obesity or type 2 diabetes. Because these accounts use pre-tax dollars, paying this way is effectively a discount equal to your tax rate — often 20–30%.

A few practical notes. You may need a Letter of Medical Necessity from your prescriber, especially if the medication is being used for weight management rather than diabetes. Keep your receipts and prescription records in case your plan administrator asks for documentation. And remember FSA funds are typically "use it or lose it" within the plan year, while HSA funds roll over indefinitely.

Stacking strategies is where real savings happen: you can often use a manufacturer savings card and pay the remaining copay with FSA or HSA dollars. For a full walkthrough of the tax mechanics and what documentation to keep, see our guide to [using FSA and HSA funds for GLP-1s](/blog/glp1-fsa-hsa-pre-tax-dollars-save-on-weight-loss-2026).

Start by finding out exactly what your insurance covers. Call the number on your card or check your plan's formulary for "Wegovy" or "Zepbound." Many plans cover the diabetes versions (Ozempic, Mounjaro) but not the weight-loss versions, so ask specifically.

If it's covered, enroll in the manufacturer savings card and ask your pharmacist to run it — this is the $25/month path. If your plan requires prior authorization, ask your prescriber's office to submit it; a documented history of weight-related health issues improves approval odds.

If it's not covered, compare the manufacturer cash programs (NovoCare, LillyDirect) against any telehealth cash offers, and factor in whether you'd rather take semaglutide or tirzepatide. Then layer in FSA/HSA dollars to shave off your tax rate.

Finally, revisit this every few months. Pricing, introductory offers, and coverage rules change frequently, and switching drugs or programs can meaningfully change your bill. If your medication choice is still open, comparing [Ozempic and Wegovy](/blog/ozempic-vs-wegovy-same-drug-different-purpose-2026) clarifies why the same molecule carries different prices under different brand names.